Article Text

Download PDFPDF
Embolization of the middle meningeal artery for the treatment of chronic subdural hematoma: considerations for pragmatic trial design

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @JoshuaAHirsch, @AdamArthurMD

  • Contributors All authors contributed equally to this submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests DF: Medtronic – Consulting, Proctoring; Cerenovous – Consulting; Microvention – Consulting, Proctoring, Research Support; Penumbra – Research Support; Stryker – Consulting, Research Support; Balt USA – Consulting, Research Support; Siemens – Research Support; MENTICE-Vascular Simulations – Stock Holder, Consultant; Neurogami – Stock Holder, Consultant; Marblehead – Consultant, Stock Holder; RAPID.AI – Consultant; RAPID Medical – Consultant; Qapel Medical – Honorarium, Consultant; Arsenal Medical – Consultant.Consultant—MedtronicDMC member—RelievantGrant recipient—Neiman Health Policy Institute.

    JAH: Consultant—Medtronic; DMC member—Relievant; Grant recipient—Neiman Health Policy Institute.

    ASA: Consultant for Balt, J and J, Medtronic, Microvention, Penumbra, Scientia, Serenity, Stryker. Research support from Balt, Medtronic, Microvention, Penumbra, Siemens.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles